SecSonar.com

Biogen Inc. (BIIB)

Biogen Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Biogen Inc. (BIIB) is a Drug Manufacturers - General company based in US with a market capitalization of $29.2B. Revenue grew 1.4% year-over-year and the company generated $2.1B in free cash flow. This page tracks BIIB's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 7.61K employees · IPO Sep 17, 1991

Valuation

Valuation & price

$192.95 · as of May 17, 2026 · -10.9% vs 52w high

21.9

P/E ratio

Latest-FY diluted EPS

1.60

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$216$169$123Jul 25Dec 25Jul 26Jul 7, 25$130.13Jul 9, 25$133.02Jul 11, 25$134.21Jul 15, 25$127.50Jul 17, 25$128.69Jul 21, 25$122.68Jul 23, 25$130.98Jul 25, 25$131.52Jul 29, 25$127.90Jul 31, 25$128.00Aug 4, 25$132.20Aug 6, 25$129.34Aug 11, 25$128.00Aug 13, 25$135.19Aug 15, 25$138.60Aug 19, 25$138.86Aug 21, 25$139.12Aug 25, 25$136.36Aug 27, 25$136.36Aug 29, 25$132.22Sep 3, 25$141.62Sep 5, 25$140.67Sep 9, 25$143.60Sep 11, 25$148.84Sep 16, 25$143.68Sep 18, 25$143.81Sep 22, 25$140.66Sep 24, 25$137.67Sep 26, 25$137.37Sep 30, 25$140.08Oct 2, 25$155.25Oct 6, 25$154.05Oct 8, 25$150.97Oct 10, 25$146.57Oct 14, 25$145.31Oct 16, 25$142.26Oct 21, 25$146.22Oct 23, 25$150.08Oct 27, 25$150.43Oct 29, 25$147.86Oct 31, 25$154.27Nov 4, 25$149.33Nov 6, 25$156.74Nov 10, 25$156.26Nov 12, 25$161.48Nov 14, 25$167.55Nov 18, 25$168.83Nov 20, 25$168.18Nov 25, 25$181.96Nov 28, 25$182.09Dec 2, 25$180.18Dec 4, 25$181.98Dec 8, 25$180.44Dec 10, 25$177.55Dec 12, 25$174.10Dec 16, 25$171.50Dec 18, 25$169.91Dec 22, 25$174.70Dec 24, 25$176.33Dec 29, 25$176.83Jan 2, 26$177.82Jan 6, 26$182.61Jan 8, 26$186.00Jan 12, 26$185.63Jan 14, 26$169.31Jan 16, 26$164.42Jan 21, 26$172.62Jan 23, 26$171.59Jan 27, 26$174.12Jan 29, 26$176.18Feb 2, 26$179.09Feb 4, 26$185.45Feb 9, 26$193.81Feb 11, 26$191.20Feb 13, 26$196.52Feb 18, 26$194.13Feb 20, 26$192.03Feb 24, 26$195.13Feb 26, 26$188.02Mar 2, 26$188.05Mar 4, 26$189.94Mar 6, 26$184.87Mar 10, 26$188.41Mar 12, 26$184.90Mar 17, 26$185.29Mar 19, 26$183.41Mar 23, 26$183.64Mar 25, 26$189.18Mar 27, 26$183.84Mar 31, 26$183.33Apr 2, 26$177.34Apr 7, 26$175.61Apr 9, 26$177.11Apr 13, 26$176.37Apr 15, 26$180.54Apr 17, 26$177.35Apr 22, 26$190.07Apr 24, 26$184.38Apr 28, 26$183.38Apr 30, 26$189.28May 4, 26$187.21May 6, 26$190.68May 8, 26$193.45May 12, 26$199.36May 14, 26$191.37May 18, 26$191.91May 20, 26$187.80May 22, 26$193.76May 28, 26$196.39Jun 1, 26$192.23Jun 3, 26$195.96Jun 5, 26$195.34Jun 9, 26$199.10Jun 11, 26$199.96Jun 15, 26$198.64Jun 17, 26$198.67Jun 22, 26$199.71Jun 24, 26$199.59Jun 26, 26$216.03Jul 2, 26$216.12
$122.6852-week range$216.63
Loading valuation history…

Fundamentals

Key fundamentals

$29.2B

Market cap

1.4%

Revenue growth (YoY)

70.5%

Gross margin

$2.1B

Free cash flow (USD)

$3.1B

Net debt

0.7%

Share dilution

3/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$11.4BFY 2017$12.3BFY 2018$13.5BFY 2019$14.4BFY 2020$13.4BFY 2021$11.0BFY 2022$10.2BFY 2023$9.8BFY 2024$9.7BFY 2025$9.8B
$11.4B$9.8B

Free cash flow by year

2016 → 2025

FY 2016$3.9BFY 2017$3.7BFY 2018$5.4BFY 2019$6.6BFY 2020$3.8BFY 2021$3.4BFY 2022$1.1BFY 2023$1.2BFY 2024$2.5BFY 2025$2.1B
$3.9B$2.1B

Gross margin by year

2021 → 2025

FY 202180.8%FY 202277.6%FY 202374.2%FY 202476.1%FY 202570.5%
80.8%70.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 29, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventEarnings GuidanceJul 1, 2026Filing
  • 8-K eventAcquisition AmendmentJun 10, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 10, 2026Filing
  • 8-K eventDebt RefinancingMay 14, 2026Filing
  • 8-K eventEarnings ReleaseApr 29, 2026Filing
  • Quarterly report10-Q FiledApr 29, 2026Filing
  • 8-K eventEarnings ReleaseApr 6, 2026Filing
  • 8-K eventMerger AgreementMar 31, 2026Filing

Questions

Frequently asked questions

What is Biogen Inc.'s market cap?

Biogen Inc. (BIIB) has a market capitalization of $29.2B.

What is BIIB's P/E ratio?

BIIB trades at a price-to-earnings ratio of 21.9, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is BIIB's price-to-book (P/B) ratio?

BIIB trades at 1.60 times book value per share.

Are insiders buying BIIB stock?

SEC Form 4 filings show no open-market insider buys at Biogen Inc. in the last 90 days (0 sells).

Same arena

Related companies in Drug Manufacturers - General

ZTS

Zoetis Inc.

$32.6B

GRFS

Grifols, S.A.

$6.7B

OGN

Organon & Co.

$3.5B

SCLX

Scilex Holding Company

$79M

SRXH

SRx Health Solutions Inc.

$3.9M

GSK

GSK plc

$101.9B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.